NFKB1 and hepatocellular carcinoma: For example, Mir26b appears to suppress the nuclear factor-kappa B (NF-κB) pathway in human hepatocellular carcinoma cell lines by inhibiting the expression of TGF-activated kinase-1 (TAK1) and TAK1-binding protein-3, both of which are positive regulators of the NF-κB system (Zhao et al., 2014).